Arqule Inc Quick Ratio (ARQL) starting from the third quarter 2019 to third quarter 2018, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Arqule Inc  (ARQL)

Arqule Inc's Quick Ratio

ARQL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2019, Quick Ratio fell to 8.38 above Arqule Inc average.

Within Major Pharmaceutical Preparations industry 135 other companies have achieved higher Quick Ratio than Arqule Inc in third quarter 2019. While Quick Ratio total ranking in the third quarter 2019 has deteriorated compared to the prior quarter from 166 to 380.

Explain Quick Ratio?
How much Cash & cash equivalents ARQL´s has?
What are ARQL´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ARQL Quick Ratio (Sep 30 2019)
Q3		 (Jun 30 2019)
Q2		 (Mar 31 2019)
Q1		 (Dec 31 2018)
Q4		 (Sep 30 2018)
Q3
Y / Y Current Liabilities Change 33.47 % 67.48 % 74.85 % 49.76 % 38.43 %
Y / Y Cash & cash equivalent Change 24.99 % 288.76 % 115.05 % 107.26 % 262.94 %
Quick Ratio MRQ 8.38 12.83 6.38 6.81 8.95
ARQL's Total Ranking # 380 # 166 # 95 # 423 # 355
Seq. Current Liabilities Change 6.96 % -3.44 % -1.07 % 30.63 % 34.21 %
Seq. Cash & cash equivalent Change -30.1 % 94.23 % -7.37 % -0.62 % 117.43 %



Quick Ratio third quarter 2019 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 136
Healthcare Sector # 189
Overall Market # 380


Quick Ratio Statistics
High Average Low
12.83 4.39 1.41
(Jun 30 2019)   (Dec 31 2011)




Financial Statements
Arqule Inc's Current Liabilities $ 15 Millions Visit ARQL's Balance sheet
Arqule Inc's Cash & cash equivalent $ 125 Millions Visit ARQL's Balance sheet
Source of ARQL's Sales Visit ARQL's Sales by Geography


Cumulative Arqule Inc's Quick Ratio

ARQL's Quick Ratio for the trailling 12 Months

ARQL Quick Ratio

 (Sep 30 2019)
12 Months		 (Jun 30 2019)
12 Months		 (Mar 31 2019)
12 Months		 (Dec 31 2018)
12 Months		 (Sep 30 2018)
12 Months
Y / Y Current Liabilities TTM Growth 54.36 % 57.41 % 45.63 % 31.43 % 20.33 %
Y / Y Cash & cash equivalent TTM Growth 109.18 % 186.2 % 126.07 % 100.23 % 86.35 %
Quick Ratio TTM 8.56 8.69 6.96 6.81 6.32
Total Ranking TTM # 4182 # 231 # 271 # 176 # 4119
Seq. Current Liabilities TTM Growth 6.91 % 11.57 % 14.59 % 12.93 % 9.02 %
Seq. Cash & cash equivalent TTM Growth 5.31 % 39.36 % 17.09 % 21.72 % 44.09 %

Quick ratio ranking by company, industry and sector >> Back to ARQL Financial Strength Comparisons >> Go to Compare ARQL Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2019 to $14.93 millions, cumulative Quick Ratio decreased to 8.56 above the ARQL average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 446 other companies have achieved higher Quick Ratio than Arqule Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2019 from 231 to 4182.

Explain Quick Ratio?
How much Cash & cash equivalents ARQL´s has?
What are ARQL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 447
Healthcare Sector # 848
Within the Market # 4182


trailing twelve months Quick Ratio Statistics
High Average Low
8.51 4.44 3.12
(Jun 30 2019)   (Mar 31 2015)




Companies with similar Quick Ratio in the quarter ending Sep 30 2019, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2019 MRQ Cash & cash equivalentSep 30 2019 MRQ Current Liabilities
Ideaya Biosciences Inc   22.64 $ 109.356  Millions$ 4.831  Millions
Phasebio Pharmaceuticals Inc.  22.41 $ 81.771  Millions$ 3.649  Millions
Fulcrum Therapeutics Inc   20.31 $ 101.597  Millions$ 5.002  Millions
Satsuma Pharmaceuticals Inc   20.03 $ 118.948  Millions$ 5.938  Millions
Cryoport inc   19.99 $ 93.909  Millions$ 4.698  Millions
Xbiotech Inc   19.96 $ 40.338  Millions$ 2.021  Millions
Filana Therapeutics Inc   19.63 $ 17.804  Millions$ 0.907  Millions
Applied Therapeutics Inc   19.52 $ 32.954  Millions$ 1.688  Millions
Kura Oncology Inc   19.44 $ 250.126  Millions$ 12.865  Millions
Provention Bio Inc   19.17 $ 95.088  Millions$ 4.960  Millions
Seres Therapeutics Inc   18.81 $ 83.788  Millions$ 4.455  Millions
Synthorx, Inc.  18.06 $ 150.886  Millions$ 8.357  Millions
Principia Biopharma Inc   17.84 $ 150.704  Millions$ 8.449  Millions
Crinetics Pharmaceuticals Inc   16.71 $ 131.673  Millions$ 7.882  Millions
Dianthus Therapeutics Inc   16.68 $ 160.570  Millions$ 9.629  Millions
Verrica Pharmaceuticals Inc   16.42 $ 71.078  Millions$ 4.330  Millions
Crescent Biopharma Inc   16.38 $ 170.939  Millions$ 10.436  Millions
Marker Therapeutics inc   16.23 $ 48.500  Millions$ 2.988  Millions
Kezar Life Sciences Inc   16.00 $ 85.243  Millions$ 5.327  Millions
Milestone Pharmaceuticals Inc   15.45 $ 136.501  Millions$ 8.836  Millions
Matinas Biopharma Holdings Inc   15.20 $ 32.665  Millions$ 2.149  Millions
Deciphera Pharmaceuticals Inc   15.17 $ 634.595  Millions$ 41.841  Millions
Global Blood Therapeutics Inc.  14.64 $ 603.104  Millions$ 41.193  Millions
Equillium Inc   14.56 $ 62.238  Millions$ 4.274  Millions
Boundless Bio Inc   14.37 $ 351.464  Millions$ 24.455  Millions
Cnbx Pharmaceuticals Inc   14.30 $ 6.277  Millions$ 0.439  Millions
Anaptysbio Inc   14.16 $ 421.002  Millions$ 29.730  Millions
G1 Therapeutics Inc   14.13 $ 299.933  Millions$ 21.222  Millions
Enanta Pharmaceuticals Inc  13.82 $ 335.236  Millions$ 24.259  Millions
Ngm Biopharmaceuticals Inc   13.79 $ 356.573  Millions$ 25.854  Millions

Date modified: 2026-09-18T13:11:03+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.